Techno Drugs Ltd. (DSE:TECHNODRUG)

Techno Drugs Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Revenue	2,993	3,613	2,733	5,029
Revenue Growth (YoY)	9.49%	32.19%	-45.64%	-
Cost of Revenue	1,697	2,098	1,579	3,224
Gross Profit	1,296	1,515	1,154	1,804
Selling, General & Admin	710.69	848.23	628.04	905.09
Operating Expenses	710.69	848.23	628.04	905.09
Operating Income	585.34	666.8	526	899.4
Interest Expense	-326.32	-305.93	-263.87	-256.61
Interest & Investment Income	2.55	2.55	2.62	11.97
Currency Exchange Gain (Loss)	-0.19	-0.19	-0.01	-
Other Non Operating Income (Expenses)	-2.74	-3.64	-5.69	-3.74
Pretax Income	258.64	359.59	259.05	651.02
Income Tax Expense	39.91	78.99	63.55	171.24
Net Income	218.74	280.6	195.51	479.78
Net Income to Common	218.74	280.6	195.51	479.78
Net Income Growth	11.88%	43.53%	-59.25%	-
Shares Outstanding (Basic)	114	95	94	94
Shares Outstanding (Diluted)	114	95	94	94
Shares Change (YoY)	21.18%	1.34%	-	-
EPS (Basic)	1.92	2.94	2.08	5.10
EPS (Diluted)	1.92	2.94	2.08	5.10
EPS Growth	-7.67%	41.62%	-59.25%	-
Free Cash Flow	-428.2	83.64	-416.28	-1.52
Free Cash Flow Per Share	-3.75	0.88	-4.42	-0.02
Dividend Per Share	-	1.200	-	-
Gross Margin	43.30%	41.93%	42.22%	35.88%
Operating Margin	19.56%	18.45%	19.24%	17.89%
Profit Margin	7.31%	7.77%	7.15%	9.54%
Free Cash Flow Margin	-14.31%	2.31%	-15.23%	-0.03%
EBITDA	925.58	990.74	817.36	1,151
EBITDA Margin	30.93%	27.42%	29.90%	22.89%
D&A For EBITDA	340.23	323.94	291.35	251.54
EBIT	585.34	666.8	526	899.4
EBIT Margin	19.56%	18.45%	19.24%	17.89%
Effective Tax Rate	15.43%	21.97%	24.53%	26.30%
Advertising Expenses	-	0.76	0.26	0.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.